You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameIrbesartan
Accession NumberDB01029  (APRD00413)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionIrbesartan is an angiotensin receptor blocker (ARB) used mainly for the treatment of hypertension. It competes with angiotensin II for binding at the AT1 receptor subtype. Unlike ACE inhibitors, ARBs do not have the adverse effect of dry cough. The use of ARBs is pending revision due to findings from several clinical trials suggesting that this class of drugs may be associated with a small increased risk of cancer.
Structure
Thumb
Synonyms
2-Butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
Avapro
BMS 186295
Irbesartan
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act IrbesartanTablet75 mgOralActavis Pharma Company2011-03-21Not applicableCanada
Act IrbesartanTablet150 mgOralActavis Pharma Company2011-03-21Not applicableCanada
Act IrbesartanTablet300 mgOralActavis Pharma Company2011-03-21Not applicableCanada
AprovelTablet300 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet, film coated150 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet, film coated300 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet75 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet, film coated75 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet, film coated150 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet75 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet, film coated300 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet150 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet, film coated150 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet, film coated300 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet75 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet, film coated150 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet75 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet, film coated75 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet, film coated300 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet150 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet, film coated300 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet300 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet, film coated150 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet, film coated75 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet150 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet, film coated300 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet, film coated75 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet150 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet, film coated75 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet300 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet, film coated300 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet300 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet, film coated150 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet, film coated150 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet, film coated300 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet300 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet150 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet, film coated75 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet, film coated150 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet75 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet, film coated75 mgOralSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet, film coated75 mgOralSanofi Clir Snc1997-08-27Not applicableEu
Auro-irbesartanTablet75 mgOralAuro Pharma Inc2013-07-08Not applicableCanada
Auro-irbesartanTablet150 mgOralAuro Pharma Inc2013-07-08Not applicableCanada
Auro-irbesartanTablet300 mgOralAuro Pharma Inc2013-07-08Not applicableCanada
Ava-irbesartanTablet75 mgOralAvanstra Inc2011-11-232014-08-21Canada
Ava-irbesartanTablet150 mgOralAvanstra Inc2011-11-232014-08-21Canada
Ava-irbesartanTablet300 mgOralAvanstra Inc2011-11-232014-08-21Canada
AvaproTablet150 mg/1OralCardinal Health1997-09-30Not applicableUs
AvaproTablet150 mg/1OralSanofi Aventis U.S. Llc2013-01-01Not applicableUs
AvaproTablet150 mg/1OralBristol Myers Squibb Company1997-09-302016-03-31Us
AvaproTablet150 mgOralSanofi Aventis Canada Inc1998-07-22Not applicableCanada
AvaproTablet150 mg/1OralLake Erie Medical DBA Quality Care Products LLC2013-01-01Not applicableUs
AvaproTablet150 mg/1Oralbryant ranch prepack1997-09-30Not applicableUs
AvaproTablet300 mg/1OralSanofi Aventis U.S. Llc2013-01-01Not applicableUs
AvaproTablet300 mg/1OralBristol Myers Squibb Company1997-09-302016-03-31Us
AvaproTablet300 mgOralSanofi Aventis Canada Inc1998-07-22Not applicableCanada
AvaproTablet150 mg/1OralPhysicians Total Care, Inc.2000-11-21Not applicableUs
AvaproTablet300 mg/1Oralbryant ranch prepack1997-09-30Not applicableUs
AvaproTablet300 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-23Not applicableUs
AvaproTablet300 mg/1OralPhysicians Total Care, Inc.2004-05-10Not applicableUs
AvaproTablet75 mgOralSanofi Aventis Canada Inc1998-06-22Not applicableCanada
AvaproTablet150 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-23Not applicableUs
AvaproTablet75 mg/1OralSanofi Aventis U.S. Llc2013-01-01Not applicableUs
Bio-irbesartanTablet75 mgOralBiomed Pharma2016-08-17Not applicableCanada
Bio-irbesartanTablet150 mgOralBiomed Pharma2016-08-17Not applicableCanada
Bio-irbesartanTablet300 mgOralBiomed Pharma2016-08-17Not applicableCanada
Dom-irbesartanTablet75 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-irbesartanTablet150 mgOralDominion Pharmacal2013-06-28Not applicableCanada
Dom-irbesartanTablet300 mgOralDominion PharmacalNot applicableNot applicableCanada
Ipg-irbesartanTablet75 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-irbesartanTablet150 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-irbesartanTablet300 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
IrbesartanTablet300 mgOralSanis Health Inc2011-10-18Not applicableCanada
IrbesartanTablet300 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
IrbesartanTablet300 mgOralJubilant Generics LimitedNot applicableNot applicableCanada
IrbesartanTablet75 mgOralSivem Pharmaceuticals Ulc2012-06-10Not applicableCanada
IrbesartanTablet75 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
IrbesartanTablet75 mgOralPro Doc Limitee2011-05-27Not applicableCanada
IrbesartanTablet75 mgOralSanis Health Inc2011-10-18Not applicableCanada
IrbesartanTablet75 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
IrbesartanTablet150 mgOralSivem Pharmaceuticals Ulc2012-06-10Not applicableCanada
IrbesartanTablet150 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
IrbesartanTablet150 mgOralPro Doc Limitee2011-05-27Not applicableCanada
IrbesartanTablet75 mgOralJubilant Generics LimitedNot applicableNot applicableCanada
IrbesartanTablet150 mgOralSanis Health Inc2011-10-18Not applicableCanada
IrbesartanTablet150 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
IrbesartanTablet300 mgOralSivem Pharmaceuticals Ulc2012-06-10Not applicableCanada
IrbesartanTablet300 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
IrbesartanTablet300 mgOralPro Doc Limitee2011-05-27Not applicableCanada
IrbesartanTablet150 mgOralJubilant Generics LimitedNot applicableNot applicableCanada
Irbesartan ZentivaTablet300 mgOralSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet, film coated300 mgOralSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet150 mgOralSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet, film coated150 mgOralSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet, film coated300 mgOralSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet75 mgOralSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet, film coated75 mgOralSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet, film coated75 mgOralSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet300 mgOralSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet, film coated150 mgOralSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet75 mgOralSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet, film coated75 mgOralSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet, film coated300 mgOralSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet, film coated150 mgOralSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet, film coated300 mgOralSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet150 mgOralSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet75 mgOralSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet, film coated75 mgOralSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet, film coated75 mgOralSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet300 mgOralSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet, film coated300 mgOralSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet, film coated75 mgOralSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet, film coated300 mgOralSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet75 mgOralSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet150 mgOralSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet, film coated150 mgOralSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet150 mgOralSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet, film coated75 mgOralSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet, film coated150 mgOralSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet300 mgOralSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet, film coated300 mgOralSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet75 mgOralSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet, film coated75 mgOralSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet, film coated300 mgOralSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet300 mgOralSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet, film coated150 mgOralSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet150 mgOralSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet, film coated150 mgOralSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet, film coated150 mgOralSanofi Aventis Groupe  2007-01-19Not applicableEu
Jamp-irbesartanTablet150 mgOralJamp Pharma Corporation2014-01-15Not applicableCanada
Jamp-irbesartanTablet300 mgOralJamp Pharma Corporation2014-01-15Not applicableCanada
Jamp-irbesartanTablet75 mgOralJamp Pharma Corporation2014-01-15Not applicableCanada
KarveaTablet, film coated300 mgOralSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet150 mgOralSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet, film coated150 mgOralSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet150 mgOralSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet, film coated300 mgOralSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet75 mgOralSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet, film coated150 mgOralSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet75 mgOralSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet, film coated75 mgOralSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet, film coated300 mgOralSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet300 mgOralSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet, film coated150 mgOralSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet, film coated75 mgOralSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet300 mgOralSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet, film coated300 mgOralSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet150 mgOralSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet, film coated300 mgOralSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet150 mgOralSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet, film coated75 mgOralSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet, film coated75 mgOralSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet300 mgOralSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet, film coated150 mgOralSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet, film coated150 mgOralSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet75 mgOralSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet, film coated75 mgOralSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet, film coated75 mgOralSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet300 mgOralSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet, film coated300 mgOralSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet150 mgOralSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet, film coated75 mgOralSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet, film coated150 mgOralSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet300 mgOralSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet, film coated150 mgOralSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet, film coated300 mgOralSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet75 mgOralSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet, film coated75 mgOralSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet, film coated150 mgOralSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet75 mgOralSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet, film coated300 mgOralSanofi Aventis Groupe1997-08-27Not applicableEu
Mar-irbesartanTablet150 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-irbesartanTablet300 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-irbesartanTablet75 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mint-irbesartanTablet300 mgOralMint Pharmaceuticals Inc2015-01-14Not applicableCanada
Mint-irbesartanTablet75 mgOralMint Pharmaceuticals Inc2015-01-14Not applicableCanada
Mint-irbesartanTablet150 mgOralMint Pharmaceuticals Inc2015-01-14Not applicableCanada
Mylan-irbesartanTablet300 mgOralMylan Pharmaceuticals Ulc2011-11-30Not applicableCanada
Mylan-irbesartanTablet75 mgOralMylan Pharmaceuticals Ulc2011-11-30Not applicableCanada
Mylan-irbesartanTablet150 mgOralMylan Pharmaceuticals Ulc2011-11-30Not applicableCanada
Ntp-irbesartanTablet75 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-irbesartanTablet150 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-irbesartanTablet300 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Pendo-irbesartanTablet300 mgOralPendopharm Division Of De Pharmascience IncNot applicableNot applicableCanada
PMS-irbesartanTablet75 mgOralPharmascience Inc2011-03-24Not applicableCanada
PMS-irbesartanTablet150 mgOralPharmascience Inc2011-03-24Not applicableCanada
PMS-irbesartanTablet300 mgOralPharmascience Inc2011-03-24Not applicableCanada
Priva-irbesartanTablet75 mgOralPharmapar Inc2016-05-13Not applicableCanada
Priva-irbesartanTablet150 mgOralPharmapar Inc2016-08-17Not applicableCanada
Priva-irbesartanTablet300 mgOralPharmapar Inc2016-05-13Not applicableCanada
Q-irbesartanTablet75 mgOralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-irbesartanTablet150 mgOralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-irbesartanTablet300 mgOralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Ran-irbesartanTablet150 mgOralRanbaxy Pharmaceuticals Canada Inc.2013-07-24Not applicableCanada
Ran-irbesartanTablet300 mgOralRanbaxy Pharmaceuticals Canada Inc.2013-07-24Not applicableCanada
Ran-irbesartanTablet75 mgOralRanbaxy Pharmaceuticals Canada Inc.2013-07-24Not applicableCanada
Ratio-irbesartanTablet75 mgOralTeva Canada Limited2011-03-21Not applicableCanada
Ratio-irbesartanTablet150 mgOralTeva Canada Limited2011-03-21Not applicableCanada
Ratio-irbesartanTablet300 mgOralTeva Canada Limited2011-03-21Not applicableCanada
Riva-irbesartanTablet300 mgOralLaboratoire Riva Inc2014-12-03Not applicableCanada
Riva-irbesartanTablet75 mgOralLaboratoire Riva Inc2014-12-03Not applicableCanada
Riva-irbesartanTablet150 mgOralLaboratoire Riva Inc2014-12-03Not applicableCanada
Sandoz IrbesartanTablet150 mgOralSandoz Canada Incorporated2011-03-21Not applicableCanada
Sandoz IrbesartanTablet300 mgOralSandoz Canada Incorporated2011-03-21Not applicableCanada
Sandoz IrbesartanTablet75 mgOralSandoz Canada Incorporated2011-03-21Not applicableCanada
Teva-irbesartanTablet300 mgOralTeva Canada Limited2011-03-21Not applicableCanada
Teva-irbesartanTablet75 mgOralTeva Canada Limited2011-03-21Not applicableCanada
Teva-irbesartanTablet150 mgOralTeva Canada Limited2011-03-21Not applicableCanada
Van-irbesartanTablet300 mgOralVanc Pharmaceuticals Inc2015-06-08Not applicableCanada
Van-irbesartanTablet75 mgOralVanc Pharmaceuticals Inc2015-06-08Not applicableCanada
Van-irbesartanTablet150 mgOralVanc Pharmaceuticals Inc2015-06-08Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-irbesartanTablet75 mgOralApotex Inc2012-09-25Not applicableCanada
Apo-irbesartanTablet150 mgOralApotex Inc2012-09-25Not applicableCanada
Apo-irbesartanTablet300 mgOralApotex Inc2012-09-25Not applicableCanada
IrbesartanTablet, film coated75 mg/1OralApotex Corp.2012-10-16Not applicableUs
IrbesartanTablet75 mg/1OralAurobindo Pharma Limited2012-09-27Not applicableUs
IrbesartanTablet300 mg/1OralSolco healthcare U.S., LLC2016-06-13Not applicableUs
IrbesartanTablet150 mg/1OralAjanta Pharma Limited2015-01-20Not applicableUs
IrbesartanTablet150 mg/1Oralbryant ranch prepack2013-05-10Not applicableUs
IrbesartanTablet300 mg/1OralTeva Pharmaceuticals Usa, Inc.2013-05-102017-02-28Us
IrbesartanTablet150 mg/1OralProficient Rx LP2012-03-30Not applicableUs
IrbesartanTablet150 mg/1OralCamber Pharmaceuticals, Inc.2016-10-06Not applicableUs
IrbesartanTablet300 mg/1OralA S Medication Solutions2012-09-27Not applicableUs
IrbesartanTablet, coated75 mg/1OralWatson Laboratories, Inc.2012-10-162016-10-13Us
IrbesartanTablet300 mg/1OralGolden State Medical Supply, Inc.2016-02-05Not applicableUs
IrbesartanTablet75 mg/1OralScie Gen Pharmaceuticals, Inc.2015-12-07Not applicableUs
IrbesartanTablet75 mg/1OralAlembic Pharmaceuticals Inc.2016-07-01Not applicableUs
IrbesartanTablet300 mg/1OralCamber Pharmaceuticals, Inc.2012-09-27Not applicableUs
IrbesartanTablet150 mg/1OralAmerican Health Packaging2013-10-162015-12-29Us
IrbesartanTablet150 mg/1OralWest Ward Pharmaceuticals Corp.2012-10-15Not applicableUs
IrbesartanTablet75 mg/1OralLupin Pharmaceuticals, Inc.2012-10-23Not applicableUs
IrbesartanTablet150 mg/1OralUnichem Pharmaceuticals (USA), Inc.2016-04-01Not applicableUs
IrbesartanTablet, film coated300 mg/1OralHisun Pharmaceuticals Usa Inc.2016-06-14Not applicableUs
IrbesartanTablet300 mg/1OralAv Kare, Inc.2016-10-06Not applicableUs
IrbesartanTablet150 mg/1OralQualitest Pharmaceuticals2012-09-302016-10-13Us
IrbesartanTablet150 mg/1OralAv Pak2015-10-27Not applicableUs
IrbesartanTablet75 mg/1OralJubilant Cadista Pharmaceuticals Inc.2015-02-24Not applicableUs
IrbesartanTablet75 mg/1OralLUPIN LIMITED2012-10-23Not applicableUs
IrbesartanTablet150 mg/1OralAmerican Health Packaging2014-12-15Not applicableUs
IrbesartanTablet, film coated150 mg/1OralApotex Corp.2012-10-16Not applicableUs
IrbesartanTablet150 mg/1OralAurobindo Pharma Limited2012-09-27Not applicableUs
IrbesartanTablet150 mg/1OralA S Medication Solutions2012-09-27Not applicableUs
IrbesartanTablet300 mg/1OralAjanta Pharma Limited2015-01-20Not applicableUs
IrbesartanTablet150 mg/1OralScie Gen Pharmaceuticals, Inc.2015-12-07Not applicableUs
IrbesartanTablet75 mg/1OralMacleods Pharmaceuticals Limited2012-09-27Not applicableUs
IrbesartanTablet75 mg/75mgOralWestminster Pharmaceuticals, Llc2016-02-01Not applicableUs
IrbesartanTablet300 mg/1OralCamber Pharmaceuticals, Inc.2016-10-06Not applicableUs
IrbesartanTablet150 mg/1OralProficient Rx LP2012-09-27Not applicableUs
IrbesartanTablet, coated150 mg/1OralWatson Laboratories, Inc.2012-10-162016-10-13Us
IrbesartanTablet300 mg/1OralUnichem Pharmaceuticals (USA), Inc.2016-04-01Not applicableUs
IrbesartanTablet150 mg/1OralAlembic Pharmaceuticals Inc.2016-07-01Not applicableUs
IrbesartanTablet75 mg/1OralSolco healthcare U.S., LLC2012-09-27Not applicableUs
IrbesartanTablet300 mg/1OralWest Ward Pharmaceuticals Corp.2012-10-15Not applicableUs
IrbesartanTablet150 mg/1OralLupin Pharmaceuticals, Inc.2012-10-23Not applicableUs
IrbesartanTablet150 mg/1OralLUPIN LIMITED2012-10-23Not applicableUs
IrbesartanTablet75 mg/1OralSolco healthcare U.S., LLC2016-06-13Not applicableUs
IrbesartanTablet300 mg/1OralQualitest Pharmaceuticals2012-09-302016-10-13Us
IrbesartanTablet300 mg/1OralAv Pak2015-10-27Not applicableUs
IrbesartanTablet150 mg/1OralJubilant Cadista Pharmaceuticals Inc.2015-02-24Not applicableUs
IrbesartanTablet75 mg/1OralCamber Pharmaceuticals, Inc.2012-09-26Not applicableUs
IrbesartanTablet150 mg/1OralLegacy Pharmaceutical Packaging2012-03-30Not applicableUs
IrbesartanTablet, film coated300 mg/1OralApotex Corp.2012-10-16Not applicableUs
IrbesartanTablet300 mg/1OralAurobindo Pharma Limited2012-09-27Not applicableUs
IrbesartanTablet300 mg/1OralA S Medication Solutions2012-10-15Not applicableUs
IrbesartanTablet, coated300 mg/1OralWatson Laboratories, Inc.2012-10-162016-10-13Us
IrbesartanTablet300 mg/1OralScie Gen Pharmaceuticals, Inc.2015-12-07Not applicableUs
IrbesartanTablet150 mg/1OralMacleods Pharmaceuticals Limited2012-09-27Not applicableUs
IrbesartanTablet150 mg/150mgOralWestminster Pharmaceuticals, Llc2016-02-01Not applicableUs
IrbesartanTablet, film coated75 mg/1OralHisun Pharmaceuticals Usa Inc.2016-06-14Not applicableUs
IrbesartanTablet75 mg/1OralAv Kare, Inc.2016-11-17Not applicableUs
IrbesartanTablet75 mg/1OralGolden State Medical Supply, Inc.2016-02-05Not applicableUs
IrbesartanTablet300 mg/1OralAlembic Pharmaceuticals Inc.2016-07-01Not applicableUs
IrbesartanTablet150 mg/1OralSolco healthcare U.S., LLC2012-09-27Not applicableUs
IrbesartanTablet75 mg/1OralTeva Pharmaceuticals Usa, Inc.2012-03-302016-10-31Us
IrbesartanTablet300 mg/1OralLupin Pharmaceuticals, Inc.2012-10-23Not applicableUs
IrbesartanTablet300 mg/1OralLUPIN LIMITED2012-10-23Not applicableUs
IrbesartanTablet150 mg/1OralSolco healthcare U.S., LLC2016-06-13Not applicableUs
IrbesartanTablet75 mg/1OralAjanta Pharma Limited2015-01-20Not applicableUs
IrbesartanTablet300 mg/1Oralbryant ranch prepack2012-09-27Not applicableUs
IrbesartanTablet300 mg/1OralJubilant Cadista Pharmaceuticals Inc.2015-02-24Not applicableUs
IrbesartanTablet150 mg/1OralCamber Pharmaceuticals, Inc.2012-09-27Not applicableUs
IrbesartanTablet150 mg/1OralAmerican Health Packaging2013-06-122015-12-29Us
IrbesartanTablet75 mg/1OralWest Ward Pharmaceuticals Corp.2012-10-15Not applicableUs
IrbesartanTablet150 mg/1OralCarilion Materials Management2012-03-302017-02-28Us
IrbesartanTablet75 mg/1OralUnichem Pharmaceuticals (USA), Inc.2016-04-01Not applicableUs
IrbesartanTablet300 mg/1OralUnit Dose Services2012-09-27Not applicableUs
IrbesartanTablet150 mg/1OralAv Kare, Inc.2016-11-17Not applicableUs
IrbesartanTablet75 mg/1OralQualitest Pharmaceuticals2012-09-302016-10-13Us
IrbesartanTablet75 mg/1OralAv Pak2015-10-27Not applicableUs
IrbesartanTablet300 mg/1OralMacleods Pharmaceuticals Limited2012-09-27Not applicableUs
IrbesartanTablet300 mg/300mgOralWestminster Pharmaceuticals, Llc2016-02-01Not applicableUs
IrbesartanTablet, film coated150 mg/1OralHisun Pharmaceuticals Usa Inc.2016-06-14Not applicableUs
IrbesartanTablet150 mg/1OralGolden State Medical Supply, Inc.2016-02-05Not applicableUs
IrbesartanTablet150 mg/1OralProficient Rx LP2012-09-27Not applicableUs
IrbesartanTablet300 mg/1OralSolco healthcare U.S., LLC2012-09-27Not applicableUs
IrbesartanTablet150 mg/1OralTeva Pharmaceuticals Usa, Inc.2012-03-302017-02-28Us
IrbesartanTablet75 mg/1OralCamber Pharmaceuticals, Inc.2016-10-06Not applicableUs
Irbesartan TevaTablet, film coated75 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated150 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated300 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated150 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated300 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated75 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated150 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated150 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated75 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated150 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated300 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated75 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated150 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated300 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated75 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated150 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated300 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated75 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated300 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated300 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated75 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated150 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated300 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated75 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated150 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated300 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated75 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated150 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated300 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated75 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated300 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated75 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated150 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated300 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated75 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated150 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated75 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated75 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated150 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated300 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated150 mgOralTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaTablet, film coated300 mgOralTeva B.V.2009-10-30Not applicableEu
SabervelTablet, film coated75 mgOralPharmathen S.A.2012-04-13Not applicableEu
SabervelTablet, film coated150 mgOralPharmathen S.A.2012-04-13Not applicableEu
SabervelTablet, film coated75 mgOralPharmathen S.A.2012-04-13Not applicableEu
SabervelTablet, film coated150 mgOralPharmathen S.A.2012-04-13Not applicableEu
SabervelTablet, film coated150 mgOralPharmathen S.A.2012-04-13Not applicableEu
SabervelTablet, film coated150 mgOralPharmathen S.A.2012-04-13Not applicableEu
SabervelTablet, film coated300 mgOralPharmathen S.A.2012-04-13Not applicableEu
SabervelTablet, film coated300 mgOralPharmathen S.A.2012-04-13Not applicableEu
SabervelTablet, film coated75 mgOralPharmathen S.A.2012-04-13Not applicableEu
SabervelTablet, film coated300 mgOralPharmathen S.A.2012-04-13Not applicableEu
SabervelTablet, film coated300 mgOralPharmathen S.A.2012-04-13Not applicableEu
SabervelTablet, film coated75 mgOralPharmathen S.A.2012-04-13Not applicableEu
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Irbesartan BmsTablet150 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet, film coated150 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet, film coated300 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet75 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet, film coated75 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet300 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet, film coated150 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet75 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet, film coated75 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet, film coated150 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet150 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet, film coated75 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet, film coated300 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet75 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet300 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet, film coated300 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet150 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet, film coated75 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet150 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet, film coated150 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet75 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet, film coated75 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet, film coated300 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet300 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet, film coated300 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet150 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet, film coated150 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet300 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet, film coated150 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet75 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet, film coated75 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet300 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet, film coated300 mgOralBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
International Brands
NameCompany
IrbesarranNot Available
LrbesartanNot Available
Brand mixtures
NameLabellerIngredients
Act Irbesartan/hctActavis Pharma Company
Apo-irbesartan/hctzApotex Inc
Auro-irbesartan HctAuro Pharma Inc
Ava-irbesartan/hctzAvanstra Inc
AvalidePhysicians Total Care, Inc.
Avalide 150/12.5 mgSanofi Aventis Canada Inc
Avalide 300/12.5 mgSanofi Aventis Canada Inc
Dom-irbesartan-hctzDominion Pharmacal
Irbesartan and HydrochlorothiazideTeva Pharmaceuticals USA Inc
Irbesartan HctSivem Pharmaceuticals Ulc
Irbesartan Hydrochlorothiazide BmsBristol Myers Squibb Pharma Eeig
Irbesartan-hctzPro Doc Limitee
Irbesartan/hctActavis Pharma Company
Irbesartan/hctzSanis Health Inc
Jamp-irbesartan and HydrochlorothiazideJamp Pharma Corporation
KarvezideSanofi Aventis Groupe
Mint-irbesartan/hctzMint Pharmaceuticals Inc
Mylan-irbesartan HctzMylan Pharmaceuticals Ulc
Ntp-irbesartan/hctzTeva Canada Limited
Pendo-irbesartan-hctzPendopharm Division Of De Pharmascience Inc
PMS-irbesartan-hctzPharmascience Inc
Ran-irbesartan HctzRanbaxy Pharmaceuticals Canada Inc.
Ratio-irbesartan HctzTeva Canada Limited
Sandoz Irbesartan HctSandoz Canada Incorporated
Teva-irbesartan/hctzTeva Canada Limited
Van-irbesartan-hctzVanc Pharmaceuticals Inc
SaltsNot Available
Categories
UNIIJ0E2756Z7N
CAS number138402-11-6
WeightAverage: 428.5294
Monoisotopic: 428.232459548
Chemical FormulaC25H28N6O
InChI KeyYOSHYTLCDANDAN-UHFFFAOYSA-N
InChI
InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)
IUPAC Name
2-butyl-3-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1,3-diazaspiro[4.4]non-1-en-4-one
SMILES
CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1
Pharmacology
IndicationFor the treatment of hypertension, as well as diabetic nephropathy with an elevated serum creatinine and proteinuria (>300 mg/day) in patients with type 2 diabetes and hypertension. Irbesartan is also used as a second line agent in the treatment of congestive heart failure.
Structured Indications
PharmacodynamicsAngiotensin II, the principal pressor agent of the renin-angiotensin system, is responsible for effects such as vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Irbesartan is a specific competitive antagonist of AT1 receptors with a much greater affinity (more than 8500-fold) for the AT1 receptor than for the AT2 receptor and no agonist activity. Irbesartan's inhibition of angiotensin II binding to the AT1 receptor leads to multiple effects including vasodilation, a reduction in the secretion of vasopressin, and reduction in the production and secretion of aldosterone. The resulting effect is a decrease in blood pressure.
Mechanism of actionIrbesartan is a nonpeptide tetrazole derivative and an angiotensin II antagonist that selectively blocks the binding of angiotensin II to the AT1 receptor. In the renin-angiotensin system, angiotensin I is converted by angiotensin-converting enzyme (ACE) to form angiotensin II. Angiotensin II stimulates the adrenal cortex to synthesize and secrete aldosterone, which decreases the excretion of sodium and increases the excretion of potassium. Angiotensin II also acts as a vasoconstrictor in vascular smooth muscle. Irbesartan, by blocking the binding of angiotensin II to the AT1 receptor, promotes vasodilation and decreases the effects of aldosterone. The negative feedback regulation of angiotensin II on renin secretion is also inhibited, but the resulting rise in plasma renin concentrations and consequent rise in angiotensin II plasma concentrations do not counteract the blood pressure–lowering effect that occurs. The action of ARBs is different from ACE inhibitors, which block the conversion of angiotensin I to angiotensin II, meaning that the production of angiotensin II is not completely inhibited, as the hormone can be formed via other enzymes. Also, unlike ACE inhibitors, irbesartan and other ARBs do not interfere with response to bradykinins and substance P, which allows for the absence of adverse effects that are present in ACE inhibitors (eg. dry cough).
TargetKindPharmacological actionActionsOrganismUniProt ID
Type-1 angiotensin II receptorProteinyes
antagonist
HumanP30556 details
Transcription factor AP-1Proteinunknown
other/unknown
HumanP05412 details
Related Articles
AbsorptionRapid and complete with an average absolute bioavailability of 60-80%. Food has no affect on bioavailability.
Volume of distribution
  • 53 to 93 L
Protein binding90% bound to serum proteins (primarily albumin and a1-acid glycoprotein) with negligible binding to cellular components of blood.
Metabolism

Hepatic. Irbesartan is metabolized via glucuronide conjugation and oxidation. In vitro studies of irbesartan oxidation by cytochrome P450 isoenzymes indicated irbesartan was oxidized primarily by 2C9; metabolism by 3A4 was negligible.

SubstrateEnzymesProduct
Irbesartan
SR 49498Details
Irbesartan
Irbesartan derivative M4Details
Irbesartan
Irbesartan derivative M5Details
Irbesartan
Irbesartan derivative M7Details
Irbesartan
Not Available
Irbesartan derivative M3Details
Irbesartan
Irbesartan derivative M8Details
Irbesartan derivative M4
Irbesartan derivative M1Details
Irbesartan derivative M1
Not Available
Irbesartan derivative M2Details
Irbesartan derivative M7
Irbesartan derivative M1Details
Irbesartan derivative M5
Irbesartan derivative M1Details
Irbesartan derivative M4
Not Available
Irbesartan derivative M6Details
Irbesartan derivative M6
Not Available
Irbesartan derivative M2Details
Route of eliminationIrbesartan is metabolized via glucuronide conjugation and oxidation. Irbesartan and its metabolites are excreted by both biliary and renal routes. Irbesartan is excreted in the milk of lactating rats.
Half life11-15 hours
Clearance
  • 157-176 mL/min
ToxicityHypotension and tachycardia; bradycardia might also occur from overdose, LD50=mg/kg(orally in rat)
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Irbesartan Action PathwayDrug actionSMP00161
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Irbesartan.Experimental
AbirateroneThe serum concentration of Irbesartan can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Irbesartan is combined with Acebutolol.Approved
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Irbesartan.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Irbesartan.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Irbesartan.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Irbesartan is combined with Acetazolamide.Approved, Vet Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Irbesartan is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Irbesartan.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Irbesartan is combined with Adapalene.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Irbesartan.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Irbesartan.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Irbesartan.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Irbesartan.Approved, Investigational
AlosetronThe metabolism of Alosetron can be decreased when combined with Irbesartan.Approved, Withdrawn
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Irbesartan.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Irbesartan.Approved, Withdrawn
AmbrisentanIrbesartan may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineIrbesartan may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Irbesartan.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Irbesartan.Approved, Withdrawn
AmiodaroneThe metabolism of Irbesartan can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Irbesartan.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Irbesartan.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Irbesartan.Approved, Illicit
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Irbesartan.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Irbesartan is combined with Amphotericin B.Approved, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Irbesartan.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Irbesartan is combined with Amyl Nitrite.Approved
AnisodamineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Anisodamine.Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Irbesartan.Approved
ApixabanThe metabolism of Apixaban can be decreased when combined with Irbesartan.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Irbesartan.Approved
ApremilastThe risk or severity of adverse effects can be increased when Irbesartan is combined with Apremilast.Approved, Investigational
AprepitantThe metabolism of Irbesartan can be increased when combined with Aprepitant.Approved, Investigational
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Irbesartan.Experimental
ArdeparinArdeparin may increase the hyperkalemic activities of Irbesartan.Approved, Withdrawn
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Irbesartan.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Irbesartan.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Irbesartan is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Irbesartan is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Irbesartan.Approved
AtazanavirThe metabolism of Atazanavir can be decreased when combined with Irbesartan.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Irbesartan.Approved
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Irbesartan.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Irbesartan is combined with Azapropazone.Withdrawn
AzelastineThe metabolism of Azelastine can be decreased when combined with Irbesartan.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Azilsartan medoxomil.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Irbesartan is combined with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Irbesartan.Experimental
BarbitalBarbital may increase the hypotensive activities of Irbesartan.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Barnidipine.Approved
BemiparinBemiparin may increase the hyperkalemic activities of Irbesartan.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Irbesartan.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Irbesartan.Withdrawn
BenoxaprofenThe risk or severity of adverse effects can be increased when Irbesartan is combined with Benoxaprofen.Withdrawn
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Irbesartan.Approved
BepridilIrbesartan may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BeraprostThe metabolism of Beraprost can be decreased when combined with Irbesartan.Investigational
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Irbesartan.Approved
BethanidineBethanidine may increase the hypotensive activities of Irbesartan.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Irbesartan is combined with Betulinic Acid.Investigational
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Irbesartan.Approved, Investigational
BimatoprostBimatoprost may increase the hypotensive activities of Irbesartan.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Irbesartan.Approved
BortezomibThe metabolism of Bortezomib can be decreased when combined with Irbesartan.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Irbesartan.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Irbesartan is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Irbesartan.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Irbesartan.Approved
BromfenacThe risk or severity of adverse effects can be increased when Irbesartan is combined with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Bromocriptine.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Irbesartan.Approved
BucillamineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Bucillamine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Irbesartan.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Bupivacaine.Approved, Investigational
BupranololIrbesartan may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Irbesartan.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Irbesartan.Approved
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Irbesartan.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Irbesartan.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Irbesartan.Approved
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Irbesartan.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Irbesartan.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Candoxatril.Experimental
CapecitabineThe metabolism of Irbesartan can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Captopril.Approved
CarbamazepineThe metabolism of Irbesartan can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Irbesartan is combined with Carbetocin.Approved
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Irbesartan.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Irbesartan.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Irbesartan is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Irbesartan.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Irbesartan.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Castanospermine.Experimental
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Irbesartan.Approved, Investigational
CeliprololIrbesartan may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Irbesartan can be increased when it is combined with Ceritinib.Approved
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Irbesartan.Withdrawn
CertoparinCertoparin may increase the hyperkalemic activities of Irbesartan.Approved
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Irbesartan.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Irbesartan.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Irbesartan.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Irbesartan.Approved
CholecalciferolThe metabolism of Irbesartan can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilazaprilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Cilnidipine.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Irbesartan.Approved
CiprofloxacinIrbesartan may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Irbesartan.Approved, Investigational, Withdrawn
ClevidipineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Irbesartan.Approved
ClonixinThe risk or severity of adverse effects can be increased when Irbesartan is combined with Clonixin.Approved
ClopidogrelThe metabolism of Irbesartan can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClotrimazoleThe metabolism of Irbesartan can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Irbesartan.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Conivaptan.Approved, Investigational
CryptenamineCryptenamine may increase the hypotensive activities of Irbesartan.Approved
CurcuminThe risk or severity of adverse effects can be increased when Irbesartan is combined with Curcumin.Investigational
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Irbesartan.Approved, Investigational
CyclosporineThe metabolism of Irbesartan can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineIrbesartan may increase the hyperkalemic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Irbesartan.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Irbesartan is combined with D-Limonene.Investigational
DabrafenibThe serum concentration of Irbesartan can be decreased when it is combined with Dabrafenib.Approved
DalteparinDalteparin may increase the hyperkalemic activities of Irbesartan.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Irbesartan is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Irbesartan.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Irbesartan.Approved, Investigational
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Irbesartan.Approved
DebrisoquinIrbesartan may increase the hypotensive activities of Debrisoquin.Approved
DeferasiroxThe serum concentration of Irbesartan can be increased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Irbesartan can be decreased when combined with Delavirdine.Approved
DeserpidineIrbesartan may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Irbesartan is combined with Desflurane.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Irbesartan.Approved, Vet Approved
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Irbesartan.Approved
DiazepamThe metabolism of Diazepam can be decreased when combined with Irbesartan.Approved, Illicit, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Irbesartan.Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Irbesartan.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Irbesartan is combined with Diclofenamide.Approved
DicoumarolThe metabolism of Dicoumarol can be decreased when combined with Irbesartan.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Irbesartan is combined with Diflunisal.Approved
DihydralazineIrbesartan may increase the hypotensive activities of Dihydralazine.Investigational
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Irbesartan.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Irbesartan is combined with Dinutuximab.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Irbesartan.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Irbesartan.Approved
DolasetronThe metabolism of Dolasetron can be decreased when combined with Irbesartan.Approved
DomperidoneThe metabolism of Domperidone can be decreased when combined with Irbesartan.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Irbesartan.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Irbesartan.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Irbesartan.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Irbesartan.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Irbesartan.Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Irbesartan.Approved, Illicit
DrospirenoneIrbesartan may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Irbesartan is combined with Droxicam.Approved
DuloxetineIrbesartan may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Irbesartan is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Irbesartan is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Irbesartan is combined with Ebselen.Investigational
EfavirenzThe metabolism of Irbesartan can be decreased when combined with Efavirenz.Approved, Investigational
EfonidipineIrbesartan may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe metabolism of Eletriptan can be decreased when combined with Irbesartan.Approved, Investigational
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Irbesartan.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Irbesartan is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Irbesartan is combined with Enalaprilat.Approved
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Irbesartan.Approved
EnzalutamideThe metabolism of Enzalutamide can be decreased when combined with Irbesartan.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Irbesartan is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Irbesartan.Approved
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Irbesartan.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Irbesartan.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Irbesartan.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Irbesartan.Approved
EstradiolThe metabolism of Estradiol can be decreased when combined with Irbesartan.Approved, Investigational, Vet Approved
EstroneThe metabolism of Estrone can be decreased when combined with Irbesartan.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Irbesartan.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Irbesartan.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Irbesartan is combined with Etanercept.Approved, Investigational
EtodolacThe metabolism of Etodolac can be decreased when combined with Irbesartan.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Irbesartan is combined with Etofenamate.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Irbesartan.Approved, Investigational
EtravirineThe metabolism of Etravirine can be decreased when combined with Irbesartan.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Irbesartan is combined with exisulind.Investigational
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Irbesartan.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Irbesartan is combined with Fenbufen.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Irbesartan.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Irbesartan is combined with Fenoprofen.Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Irbesartan.Approved
FimasartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Fimasartan.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Floctafenine.Approved, Withdrawn
FloxuridineThe metabolism of Irbesartan can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Irbesartan can be decreased when combined with Fluconazole.Approved
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Irbesartan.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Irbesartan.Approved, Illicit
FlunixinThe risk or severity of adverse effects can be increased when Irbesartan is combined with Flunixin.Vet Approved
FluorouracilThe metabolism of Irbesartan can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Irbesartan.Approved, Vet Approved
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Irbesartan.Approved, Investigational
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Irbesartan.Approved
FluvoxamineThe metabolism of Irbesartan can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Irbesartan.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Irbesartan can be increased when combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Irbesartan.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Irbesartan.Approved, Vet Approved
GavestinelThe metabolism of Gavestinel can be decreased when combined with Irbesartan.Investigational
GemfibrozilThe metabolism of Irbesartan can be decreased when combined with Gemfibrozil.Approved
GliclazideThe metabolism of Gliclazide can be decreased when combined with Irbesartan.Approved
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Irbesartan.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Irbesartan.Approved
GlyburideThe metabolism of Glyburide can be decreased when combined with Irbesartan.Approved
GuanabenzGuanabenz may increase the hypotensive activities of Irbesartan.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Irbesartan.Approved
GuanethidineIrbesartan may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Irbesartan.Approved, Investigational
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Irbesartan.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Irbesartan.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Irbesartan.Approved, Vet Approved
HeparinHeparin may increase the hyperkalemic activities of Irbesartan.Approved, Investigational
HexamethoniumIrbesartan may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Irbesartan.Approved
HigenamineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Higenamine.Investigational
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Irbesartan.Approved
HMPL-004The risk or severity of adverse effects can be increased when Irbesartan is combined with HMPL-004.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Irbesartan.Approved
HydralazineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Irbesartan.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Irbesartan.Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Irbesartan.Approved, Illicit
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Irbesartan.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Irbesartan is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Irbesartan is combined with Icatibant.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Irbesartan.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Irbesartan.Approved
IloprostIloprost may increase the hypotensive activities of Irbesartan.Approved, Investigational
ImatinibThe metabolism of Imatinib can be decreased when combined with Irbesartan.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Imipramine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Irbesartan.Approved
IndenololIrbesartan may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Irbesartan can be decreased when combined with Indinavir.Approved
indisulamThe metabolism of indisulam can be decreased when combined with Irbesartan.Investigational
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Irbesartan.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Irbesartan is combined with Indoprofen.Withdrawn
IndoraminIrbesartan may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Irbesartan.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Irbesartan.Withdrawn
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Irbesartan.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Irbesartan is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Irbesartan.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Irbesartan.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Irbesartan is combined with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Irbesartan.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Irbesartan.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Irbesartan is combined with Kebuzone.Experimental
KetamineThe metabolism of Ketamine can be decreased when combined with Irbesartan.Approved, Vet Approved
KetanserinIrbesartan may increase the hypotensive activities of Ketanserin.Investigational
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Irbesartan.Approved
KetoconazoleThe metabolism of Irbesartan can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Irbesartan.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Irbesartan is combined with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Irbesartan.Approved
LacidipineIrbesartan may increase the hypotensive activities of Lacidipine.Approved
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Irbesartan.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Irbesartan.Approved, Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Irbesartan.Approved, Investigational
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Irbesartan.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Irbesartan.Approved, Investigational
LesinuradThe metabolism of Lesinurad can be decreased when combined with Irbesartan.Approved
LevobunololThe risk or severity of adverse effects can be increased when Irbesartan is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Levobupivacaine.Approved
LevodopaIrbesartan may increase the orthostatic hypotensive activities of Levodopa.Approved
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Irbesartan.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Levosimendan.Approved, Investigational
LicofeloneThe metabolism of Licofelone can be decreased when combined with Irbesartan.Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Irbesartan.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Irbesartan.Approved
LofexidineIrbesartan may increase the hypotensive activities of Lofexidine.Approved, Investigational
LoperamideThe metabolism of Loperamide can be decreased when combined with Irbesartan.Approved
LopinavirThe metabolism of Irbesartan can be decreased when combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Irbesartan.Approved
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Irbesartan.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Irbesartan.Approved
LovastatinThe metabolism of Irbesartan can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Irbesartan is combined with Loxoprofen.Approved
LumacaftorThe serum concentration of Irbesartan can be increased when it is combined with Lumacaftor.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Irbesartan.Approved, Investigational
MacitentanIrbesartan may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Irbesartan is combined with Magnesium salicylate.Approved
ManidipineIrbesartan may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Irbesartan.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Irbesartan is combined with Masoprocol.Approved
MebanazineMebanazine may increase the hypotensive activities of Irbesartan.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Irbesartan.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Irbesartan is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Irbesartan.Approved
MelatoninThe metabolism of Melatonin can be decreased when combined with Irbesartan.Approved, Nutraceutical, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Irbesartan.Approved, Vet Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Irbesartan.Investigational, Withdrawn
MesalazineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Mesalazine.Approved
MestranolThe metabolism of Mestranol can be decreased when combined with Irbesartan.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Irbesartan is combined with Metamizole.Withdrawn
MethadoneThe metabolism of Methadone can be decreased when combined with Irbesartan.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Irbesartan.Approved
MethohexitalMethohexital may increase the hypotensive activities of Irbesartan.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Irbesartan.Approved, Vet Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Irbesartan.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Irbesartan.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Irbesartan.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Irbesartan.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Irbesartan.Approved
MetipranololThe risk or severity of adverse effects can be increased when Irbesartan is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Irbesartan.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Irbesartan.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Irbesartan.Approved
MetyrosineIrbesartan may increase the hypotensive activities of Metyrosine.Approved
MibefradilIrbesartan may increase the hypotensive activities of Mibefradil.Withdrawn
MifepristoneThe serum concentration of Irbesartan can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Irbesartan.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Irbesartan.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Irbesartan.Approved
MizoribineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Mizoribine.Investigational
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Irbesartan.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Irbesartan.Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Irbesartan.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Irbesartan.Approved, Investigational
MoxonidineIrbesartan may increase the hypotensive activities of Moxonidine.Approved
muraglitazarThe metabolism of muraglitazar can be decreased when combined with Irbesartan.Investigational
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Irbesartan.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Irbesartan is combined with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nabilone.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nadolol.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Irbesartan.Approved
NafamostatThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Naftifine.Approved
NaftopidilIrbesartan may increase the hypotensive activities of Naftopidil.Investigational
NaloxoneThe metabolism of Naloxone can be decreased when combined with Irbesartan.Approved, Vet Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Irbesartan.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Irbesartan.Approved, Investigational
NCX 4016The risk or severity of adverse effects can be increased when Irbesartan is combined with NCX 4016.Investigational
NebivololThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nebivolol.Approved, Investigational
NepafenacThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nesiritide.Approved, Investigational
NetupitantThe metabolism of Netupitant can be decreased when combined with Irbesartan.Approved
NevirapineThe metabolism of Nevirapine can be decreased when combined with Irbesartan.Approved
NialamideNialamide may increase the hypotensive activities of Irbesartan.Withdrawn
NicardipineThe metabolism of Irbesartan can be decreased when combined with Nicardipine.Approved
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Irbesartan.Approved, Vet Approved
NicorandilNicorandil may increase the hypotensive activities of Irbesartan.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Irbesartan.Approved
NifedipineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nifedipine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Irbesartan is combined with Niflumic Acid.Approved
NiguldipineIrbesartan may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Irbesartan can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineIrbesartan may increase the hypotensive activities of Nilvadipine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Irbesartan.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Irbesartan.Approved
NitrendipineIrbesartan may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nitric Oxide.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Irbesartan.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Irbesartan.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Irbesartan.Approved
ObinutuzumabIrbesartan may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Irbesartan.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Irbesartan.Approved, Investigational
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Irbesartan.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Olsalazine.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Irbesartan is combined with Omapatrilat.Investigational
OmbitasvirThe metabolism of Ombitasvir can be decreased when combined with Irbesartan.Approved
OmeprazoleThe metabolism of Irbesartan can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Irbesartan.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Irbesartan is combined with Orgotein.Vet Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Irbesartan.Approved
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Irbesartan.Approved
OxprenololIrbesartan may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Irbesartan is combined with Oxyphenbutazone.Withdrawn
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Irbesartan.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Papaverine.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Irbesartan.Approved
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Irbesartan.Approved
PargylinePargyline may increase the hypotensive activities of Irbesartan.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Irbesartan.Approved
PazopanibThe metabolism of Pazopanib can be decreased when combined with Irbesartan.Approved
PenbutololThe risk or severity of adverse effects can be increased when Irbesartan is combined with Penbutolol.Approved, Investigational
PentamidineThe metabolism of Pentamidine can be decreased when combined with Irbesartan.Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Irbesartan.Approved, Vet Approved
PentoliniumIrbesartan may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Irbesartan.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Perindopril.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Irbesartan.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Irbesartan.Withdrawn
PhenelzinePhenelzine may increase the hypotensive activities of Irbesartan.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Irbesartan.Withdrawn
PhenobarbitalThe metabolism of Irbesartan can be increased when combined with Phenobarbital.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Irbesartan.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Irbesartan.Withdrawn
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Irbesartan.Approved
PhentolaminePhentolamine may increase the hypotensive activities of Irbesartan.Approved
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Irbesartan.Approved, Vet Approved
PhenytoinThe metabolism of Irbesartan can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Irbesartan is combined with Pimecrolimus.Approved, Investigational
PinacidilIrbesartan may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Irbesartan.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Irbesartan.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Irbesartan is combined with Pipamperone.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Irbesartan is combined with Pirfenidone.Investigational
PirlindolePirlindole may increase the hypotensive activities of Irbesartan.Approved
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Irbesartan.Approved, Investigational
PitavastatinThe metabolism of Pitavastatin can be decreased when combined with Irbesartan.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Irbesartan.Withdrawn
PolythiazideIrbesartan may increase the hypotensive activities of Polythiazide.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Irbesartan.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Irbesartan is combined with Pramipexole.Approved, Investigational
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Irbesartan.Approved
PravastatinThe metabolism of Pravastatin can be decreased when combined with Irbesartan.Approved
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Irbesartan.Approved
PrimidoneThe metabolism of Irbesartan can be increased when combined with Primidone.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Irbesartan.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Irbesartan.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Irbesartan.Approved, Vet Approved
PropacetamolThe risk or severity of adverse effects can be increased when Irbesartan is combined with Propacetamol.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Irbesartan.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Irbesartan.Approved, Investigational
PTC299The risk or severity of adverse effects can be increased when Irbesartan is combined with PTC299.Investigational
PyrimethamineThe metabolism of Irbesartan can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Irbesartan.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Quinapril.Approved, Investigational
QuinidineThe metabolism of Quinidine can be decreased when combined with Irbesartan.Approved
QuinineQuinine may increase the hypotensive activities of Irbesartan.Approved
RabeprazoleThe metabolism of Irbesartan can be decreased when combined with Rabeprazole.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Ramipril.Approved
RasagilineRasagiline may increase the hypotensive activities of Irbesartan.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Irbesartan.Approved
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Irbesartan.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Irbesartan.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Irbesartan is combined with Resveratrol.Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Irbesartan.Approved
RifampicinThe metabolism of Irbesartan can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Irbesartan can be increased when combined with Rifapentine.Approved
RilmenidineIrbesartan may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Irbesartan is combined with Riociguat.Approved
RisperidoneIrbesartan may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe metabolism of Irbesartan can be decreased when combined with Ritonavir.Approved, Investigational
RituximabIrbesartan may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Irbesartan.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Irbesartan is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Ropivacaine.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Irbesartan.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Irbesartan.Approved
RotigotineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Irbesartan.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Irbesartan is combined with Salicylamide.Approved
Salicylic acidThe metabolism of Salicylic acid can be decreased when combined with Irbesartan.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Irbesartan is combined with Salsalate.Approved
SaprisartanIrbesartan may increase the hypotensive activities of Saprisartan.Experimental
SecobarbitalThe metabolism of Irbesartan can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Irbesartan.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Irbesartan.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Irbesartan.Approved, Investigational
SertralineThe metabolism of Sertraline can be decreased when combined with Irbesartan.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Irbesartan is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Irbesartan.Approved, Investigational
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Irbesartan.Approved
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Irbesartan.Approved, Investigational
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Irbesartan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Irbesartan is combined with Sodium Nitrite.Approved
SorafenibThe metabolism of Irbesartan can be decreased when combined with Sorafenib.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Irbesartan.Approved
SpiraprilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Irbesartan.Approved
SRT501The risk or severity of adverse effects can be increased when Irbesartan is combined with SRT501.Investigational
StiripentolThe metabolism of Irbesartan can be decreased when combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Irbesartan is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Sufentanil.Approved, Investigational
SulfadiazineThe metabolism of Irbesartan can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Irbesartan can be decreased when combined with Sulfamethoxazole.Approved
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Irbesartan.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Sulfasalazine.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Irbesartan.Approved
SulfisoxazoleThe metabolism of Irbesartan can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Irbesartan is combined with Sulindac.Approved
SuprofenThe metabolism of Suprofen can be decreased when combined with Irbesartan.Approved, Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Irbesartan.Approved, Investigational
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Irbesartan.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tamsulosin.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Irbesartan.Approved
TazaroteneThe metabolism of Tazarotene can be decreased when combined with Irbesartan.Approved, Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Irbesartan.Approved, Investigational
TemazepamThe metabolism of Temazepam can be decreased when combined with Irbesartan.Approved
TemocaprilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Temocapril.Experimental, Investigational
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Irbesartan.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Irbesartan is combined with Terazosin.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Irbesartan.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Irbesartan.Withdrawn
TeriflunomideThe metabolism of Irbesartan can be decreased when combined with Teriflunomide.Approved
TerlipressinIrbesartan may increase the hypotensive activities of Terlipressin.Approved, Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Irbesartan.Approved, Investigational
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Irbesartan.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Irbesartan.Approved
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Irbesartan.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Irbesartan.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Irbesartan.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tiaprofenic acid.Approved
TiboloneIrbesartan may increase the hypotensive activities of Tibolone.Approved
TicagrelorThe metabolism of Irbesartan can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Irbesartan can be decreased when combined with Ticlopidine.Approved
TicrynafenIrbesartan may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Irbesartan.Approved
TinoridineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Irbesartan.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Irbesartan.Approved
TolazolineTolazoline may increase the hypotensive activities of Irbesartan.Approved, Vet Approved
TolbutamideThe metabolism of Irbesartan can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tolmetin.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Irbesartan.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Irbesartan.Approved, Investigational
TolvaptanTolvaptan may increase the hyperkalemic activities of Irbesartan.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Irbesartan.Approved
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Irbesartan.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Irbesartan.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Irbesartan.Approved
TravoprostTravoprost may increase the hypotensive activities of Irbesartan.Approved
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Irbesartan.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Irbesartan.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Irbesartan.Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Irbesartan.Approved, Vet Approved
TrimazosinIrbesartan may increase the hypotensive activities of Trimazosin.Experimental
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Irbesartan.Approved
TrimethaphanIrbesartan may increase the hypotensive activities of Trimethaphan.Approved
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Irbesartan.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Irbesartan.Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Trisalicylate-choline.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Irbesartan.Withdrawn
UdenafilUdenafil may increase the antihypertensive activities of Irbesartan.Approved, Investigational
UnoprostoneIrbesartan may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Irbesartan.Investigational, Withdrawn
Valproic AcidThe metabolism of Irbesartan can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Irbesartan.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Irbesartan.Approved
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Irbesartan.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Irbesartan.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Irbesartan.Investigational
VinpocetineIrbesartan may increase the hypotensive activities of Vinpocetine.Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Irbesartan.Approved
VoriconazoleThe metabolism of Irbesartan can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Irbesartan.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Irbesartan.Approved
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Irbesartan.Approved, Investigational, Withdrawn
XylometazolineIrbesartan may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Irbesartan.Approved, Vet Approved
ZafirlukastThe metabolism of Irbesartan can be decreased when combined with Zafirlukast.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Irbesartan.Approved
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Irbesartan.Approved
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Irbesartan.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Irbesartan.Approved, Investigational, Withdrawn
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Irbesartan.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Irbesartan is combined with Zomepirac.Withdrawn
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Irbesartan.Approved
Food Interactions
  • Take without regard to meals.
References
Synthesis Reference

Gennady Nisnevich, “Novel synthesis of irbesartan.” U.S. Patent US20040192713, issued September 30, 2004.

US20040192713
General References
  1. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001 Sep 20;345(12):851-60. [PubMed:11565517 ]
  2. Adams MA, Trudeau L: Irbesartan: review of pharmacology and comparative properties. Can J Clin Pharmacol. 2000 Spring;7(1):22-31. [PubMed:10822210 ]
  3. Croom KF, Curran MP, Goa KL, Perry CM: Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. Drugs. 2004;64(9):999-1028. [PubMed:15101793 ]
External Links
ATC CodesC09DB05C09DA04C09CA04
AHFS Codes
  • 24:32.08
PDB EntriesNot Available
FDA labelDownload (263 KB)
MSDSDownload (57.3 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9271
Caco-2 permeable-0.5679
P-glycoprotein substrateSubstrate0.7046
P-glycoprotein inhibitor IInhibitor0.639
P-glycoprotein inhibitor IINon-inhibitor0.6458
Renal organic cation transporterNon-inhibitor0.5091
CYP450 2C9 substrateNon-substrate0.6401
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.5749
CYP450 1A2 substrateNon-inhibitor0.6782
CYP450 2C9 inhibitorInhibitor0.5928
CYP450 2D6 inhibitorNon-inhibitor0.7584
CYP450 2C19 inhibitorInhibitor0.6619
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6192
Ames testNon AMES toxic0.5238
CarcinogenicityNon-carcinogens0.7492
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7762 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9171
hERG inhibition (predictor II)Non-inhibitor0.7728
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
TabletOral150 mg/1
TabletOral150 mg
TabletOral300 mg
TabletOral300 mg/1
TabletOral75 mg
TabletOral150 mg/150mg
TabletOral300 mg/300mg
TabletOral75 mg/1
TabletOral75 mg/75mg
Tablet, coatedOral150 mg/1
Tablet, coatedOral300 mg/1
Tablet, coatedOral75 mg/1
Tablet, film coatedOral150 mg/1
Tablet, film coatedOral300 mg/1
Tablet, film coatedOral75 mg/1
TabletOral
Tablet, film coatedOral
Tablet, film coatedOral150 mg
Tablet, film coatedOral300 mg
Tablet, film coatedOral75 mg
Prices
Unit descriptionCostUnit
Avalide 300-25 mg tablet3.92USD tablet
Avalide 300-12.5 mg tablet3.63USD tablet
Avalide 150-12.5 mg tablet3.33USD tablet
Avapro 300 mg tablet2.64USD tablet
Avapro 150 mg tablet2.33USD tablet
Avapro 75 mg tablet2.21USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2057913 No1997-07-082011-03-20Canada
CA2177772 No2007-04-102016-05-30Canada
US5270317 No1994-09-302011-09-30Us
US5994348 Yes1995-12-072015-12-07Us
US6342247 Yes1995-12-072015-12-07Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point180-181 °CNot Available
logP6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00884 mg/mLALOGPS
logP4.51ALOGPS
logP5.5ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)7.4ChemAxon
pKa (Strongest Basic)4.12ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area87.13 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity136.72 m3·mol-1ChemAxon
Polarizability47.59 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as biphenyltetrazoles and derivatives. These are organic compounds containing a biphenyl attached to a tetrazole. A carbon atom of the biphenyl moiety is boned to a carbon or the nitrogen atom of the tetrazole moiety.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzoles
Sub ClassTetrazoles
Direct ParentBiphenyltetrazoles and derivatives
Alternative Parents
Substituents
  • Biphenyltetrazole
  • Biphenyl
  • Phenylmethylamine
  • Benzylamine
  • Benzenoid
  • Imidazolinone
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • 2-imidazoline
  • Tertiary amine
  • Carboxamide group
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Carboximidamide
  • Carboxylic acid derivative
  • Carboxylic acid amidine
  • Amidine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name:
AGTR1
Uniprot ID:
P30556
Molecular Weight:
41060.53 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Voigt JP, Bramlage P, Fink H: Hypophagic effect of the angiotensin AT1 receptor antagonist irbesartan in rats. Eur J Pharmacol. 2007 Jun 14;564(1-3):131-7. Epub 2007 Mar 3. [PubMed:17408613 ]
  3. Waeber B, Burnier M: AT1-receptor antagonism in hypertension: what has been learned with irbesartan? Expert Rev Cardiovasc Ther. 2003 May;1(1):23-33. [PubMed:15030294 ]
  4. Dol F, Martin G, Staels B, Mares AM, Cazaubon C, Nisato D, Bidouard JP, Janiak P, Schaeffer P, Herbert JM: Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol. 2001 Sep;38(3):395-405. [PubMed:11486244 ]
  5. Martin G, Dol F, Mares AM, Berezowski V, Staels B, Hum DW, Schaeffer P, Herbert JM: Lesion progression in apoE-deficient mice: implication of chemokines and effect of the AT1 angiotensin II receptor antagonist irbesartan. J Cardiovasc Pharmacol. 2004 Feb;43(2):191-9. [PubMed:14716205 ]
  6. van den Meiracker AH, Admiraal PJ, Janssen JA, Kroodsma JM, de Ronde WA, Boomsma F, Sissmann J, Blankestijn PJ, Mulder PG, Man In 't Veld AJ, et al.: Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension. Hypertension. 1995 Jan;25(1):22-9. [PubMed:7843749 ]
  7. Carraway JW, Park S, McCune SA, Holycross BJ, Radin MJ: Comparison of irbesartan with captopril effects on cardiac hypertrophy and gene expression in heart failure-prone male SHHF/Mcc-fa(cp) rats. J Cardiovasc Pharmacol. 1999 Mar;33(3):451-60. [PubMed:10069682 ]
  8. Hope S, Brecher P, Chobanian AV: Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis. Am J Hypertens. 1999 Jan;12(1 Pt 1):28-34. [PubMed:10075381 ]
  9. Mazzolai L, Maillard M, Rossat J, Nussberger J, Brunner HR, Burnier M: Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists. Hypertension. 1999 Mar;33(3):850-5. [PubMed:10082498 ]
  10. Morsing P, Adler G, Brandt-Eliasson U, Karp L, Ohlson K, Renberg L, Sjoquist PO, Abrahamsson T: Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. Hypertension. 1999 Jun;33(6):1406-13. [PubMed:10373224 ]
  11. Adams MA, Trudeau L: Irbesartan: review of pharmacology and comparative properties. Can J Clin Pharmacol. 2000 Spring;7(1):22-31. [PubMed:10822210 ]
  12. Croom KF, Plosker GL: Irbesartan: a review of its use in hypertension and diabetic nephropathy. Drugs. 2008;68(11):1543-69. [PubMed:18627212 ]
  13. Croom KF, Curran MP, Goa KL, Perry CM: Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. Drugs. 2004;64(9):999-1028. [PubMed:15101793 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Transcriptional activator activity, rna polymerase ii transcription factor binding
Specific Function:
Transcription factor that recognizes and binds to the enhancer heptamer motif 5'-TGA[CG]TCA-3'. Promotes activity of NR5A1 when phosphorylated by HIPK3 leading to increased steroidogenic gene expression upon cAMP signaling pathway stimulation.
Gene Name:
JUN
Uniprot ID:
P05412
Molecular Weight:
35675.32 Da
References
  1. Zhu ZS, Wang JM, Chen SL: Mesenteric artery remodeling and effects of imidapril and irbesartan on it in spontaneously hypertensive rats. World J Gastroenterol. 2004 May 15;10(10):1471-5. [PubMed:15133856 ]
  2. Cheng SM, Yang SP, Ho LJ, Tsao TP, Chang DM, Lai JH: Irbesartan inhibits human T-lymphocyte activation through downregulation of activator protein-1. Br J Pharmacol. 2004 Jul;142(6):933-42. Epub 2004 Jun 21. [PubMed:15210574 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. [PubMed:15601807 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A3
Uniprot ID:
P35503
Molecular Weight:
60337.835 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 07, 2016 02:40